^
    Back
    Association details:
    Biomarker:AHR expression
    Cancer:Solid Tumor
    Drug:IK-175 (AHR antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2020
    Title:

    448 Discovery of clinical candidate IK-175, a selective orally active AHR antagonist

    Published date:
    11/09/2020
    Excerpt:
    IK-175 inhibits AHR activity in rodent and human cancer cell lines as well as human and nonhuman primate primary immune cells, with concentration dependent effects on AHR target gene expression and cytokine release.
    DOI:
    http://dx.doi.org/10.1136/jitc-2020-SITC2020.0448